Brief: Cytodyn’S Leronlimab Decreased Mortality At 14 Days By 82% With Statistically Significant P-Value Of 0.0233 Amongst Critically Ill Covid-19 Patients
30/03/2021 12:10
March 30 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN’S LERONLIMAB DECREASED MORTALITY AT 14 DAYS BY 82%
WITH
STATISTICALLY SIGNIFICANT P-VALUE OF 0.0233 AMONGST CRITICALLY
ILL COVID-19 PATIENTS
* CYTODYN INC - PATIENTS WHO RECEIVED LERONLIMAB WERE OVER
FIVE
TIMES MORE LIKELY TO BE ALIVE AT DAY 14 THAN THOSE WHO RECEIVED
SOC ONLY
Source text for Eikon: ID:nGNX8zNz9V
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer